What Researchers Did
Researchers retrospectively reviewed cases of calcific uraemic arteriolopathy (CUA) referred for hyperbaric oxygen therapy (HBOT) to assess treatment effectiveness and identify predictive factors for wound healing and survival.
What They Found
Out of 46 identified patients with calcific uraemic arteriolopathy, 34 received a full course of hyperbaric oxygen therapy. Of these, 58% showed improved wound scores, with over half achieving complete healing, and those who benefited survived for more than 3 years on average. Diabetes was the only factor significantly associated with improved wound healing and survival.
What This Means for Canadian Patients
Canadian patients suffering from calciphylaxis, a severe condition, might consider discussing hyperbaric oxygen therapy as a potential treatment option with their physicians. This therapy could offer a chance for improved wound healing and survival, particularly for those with co-existing diabetes.
Canadian Relevance
This study has no direct Canadian connection as it was conducted outside of Canada.
Study Limitations
As a retrospective case series, this study is limited by its observational design, potential for selection bias, and lack of a control group.